NCT05625477View on ClinicalTrials.gov

Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 18, 2022

Primary Completion Date

May 29, 2022

Study Completion Date

October 18, 2022

Conditions
Tetanus
Interventions
BIOLOGICAL

TNM002 (low dose)

Single dose of TNM002 administered by intramuscular injection

BIOLOGICAL

TNM002 (medium dose)

Single dose of TNM002 administered by intramuscular injection

BIOLOGICAL

TNM002 (high dose)

Single dose of TNM002 administered by intramuscular injection

BIOLOGICAL

HTIG

Single dose of HTIG administered by intramuscular injection

BIOLOGICAL

Placebo

Single dose of placebo administered by intramuscular injection

Trial Locations (4)

Unknown

The First Affiliated Hospital of Shantou University Medical College, Shantou

Wuxi People's Hospital, Wuxi

PKUCare Luzhong Hospital, Zibo

Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming

All Listed Sponsors
lead

Zhuhai Trinomab Pharmaceutical Co., Ltd.

INDUSTRY